Condition

Metastatic Castration-resistant Prostate Cancer (mCRPC)

ClinicalTrials.gov condition label

Clinical trials22

Recruiting8

Common interventions25

Lead sponsors shown15

Clinical trials

22 shown

Green Tea and Quercetin in Combination With Docetaxel Chemotherapy in Castration-resistant Prostate Cancer PatientsNCT06615752 · 2026-10-01

Lutetium (177Lu) DGUL Combined With Pembrolizumab in Metastatic Castration-Resistant Prostate CancerNCT07244393 · 2026-07-29

A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate CancerNCT07570979 · 2026-05-25

Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate CancerNCT07493512 · 2026-04-28

A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPCNCT06241846 · 2024-02-22

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)NCT06136650 · 2023-12-18

A Study of NX-1607 in Adults With Advanced MalignanciesNCT05107674 · 2021-09-29

ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate CancerNCT03903835 · 2019-02-01

RYZ711 Diagnostic Platform StudyNCT07862582 · 2026-10-01

NOT_YET_RECRUITING

Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid TumorsNCT07570966 · 2026-06-30

PROLONG (PRostateOLaparibONcombinationGcc) StudyNCT07674121 · 2026-06-30

NOT_YET_RECRUITING

68Ga-PSMA-0057 and 177Lu-PSMA-0057 in Patients With PSMA-Positive Metastatic Castration-Resistant Prostate CancerNCT07310355 · 2025-12-30

NOT_YET_RECRUITING

Memantine Hydrochloride in Prostate Cancer PatientsNCT07164794 · 2025-11-01

NOT_YET_RECRUITING

Study of TY-302 Capsules Combined With Abiraterone in Patients With Metastatic Castration-resistant Prostate Cancer（mCRPC）NCT07104617 · 2025-08-01

NOT_YET_RECRUITING

Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid TumorsNCT06334432 · 2024-03-14

ACTIVE_NOT_RECRUITING

Phase 1 Study Evaluating Safety and Tolerability of SL-T10, GX-I7, and Pembrolizumab Triple Combination in mCRPC.NCT06344715 · 2022-10-17

Comparative Study of Abiraterone Acetate Tablets (I) or ZYTIGA® in Patients With Metastatic Castration-resistant Prostate CancerNCT04862091 · 2021-04-23

Descriptive Analysis of Clinical Outcomes in Patients With Prostate Gland Cancer, Which Spreads to Other Parts of the Body, Who Were Treated First With Novel Anti-hormone Therapy Followed by a Second Line Treatment With Novel Anti-Hormone Therapy or RadIum-223 (Xofigo).NCT03896984 · 2019-03-18

A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid TumorsNCT03811652 · 2018-12-20

INJECT: A Pilot Study of Intra-tumoral Injections in Metastatic Urological CancersNCT03071328 · 2018-01-08

A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With EnzalutamideNCT01977651 · 2013-09-25

177Lu-PSMA-617 Managed Access Program for mCRPC PatientsNCT04825652

NO_LONGER_AVAILABLE

Common interventions

Leading sponsors

Novartis Pharmaceuticals2 Advanced Accelerator Applications1 Amgen1 Astellas Pharma Global Development, Inc.1 AstraZeneca1 Bayer1 Bin Xu1 Cellbion Co., Ltd.1 Charles Drew University of Medicine and Science1 Chengdu StarRay Therapeutics Co., Ltd1 Duke University1 Jiangsu HengRui Medicine Co., Ltd.1 Karolinska Institutet1 MediLink Therapeutics (Suzhou) Co., Ltd.1 MedImmune LLC1

Trial status mix

RECRUITING8

COMPLETED5

NOT_YET_RECRUITING5

ACTIVE_NOT_RECRUITING1

NO_LONGER_AVAILABLE1

UNKNOWN1

WITHDRAWN1

Phase mix

PHASE112

PHASE29

PHASE32

EARLY_PHASE11

PHASE41

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.